Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presen... (ior to cardiac surgery. Results also sho...)

Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT

Date:11/9/2011

ior to cardiac surgery. Results also show control of platelet function as there was a rapid offset of platelet inhibition after stopping the cangrelor infusion prior to surgery."

According to 2009 data from the Organisation for Economic Co-operation and Development (OECD), more than 2.5 million PCIs are performed globally per year. Treatment guidelines in the United States and Europe recommend stent patients receive oral P2Y12 inhibitors for up to 12 months following percutaneous coronary intervention (PCI). It is estimated that up to 25 percent of these patients with stents in place will require a surgical procedure during the first five years after PCI.

Dimitrios Goundis, PhD, head of R&D at The Medicines Company added, "With strong patient enrollment in the Phase 3 PHOENIX trial of cangrelor in PCI patients and these results from the BRIDGE trial, there is great momentum with the cangrelor program, which is an important part of our portfolio of acute and intensive care hospital compounds."

Summary methods and results

The first stage of BRIDGE identified the cangrelor dose that maintains a 'thienopyridine-like' level of platelet inhibition. The second stage reported today was a prospective, randomized, double-blind, placebo-controlled trial in 210 patients with an acute coronary syndromes (ACS) or treated with a coronary stent (bare metal stent or drug eluting stent) on a thienopyridine awaiting coronary artery bypass grafting (CABG). After thienopyridine discontinuation (<72 hours), patients were administered cangrelor or placebo for at least 48 hours and up to 7 days, which was discontinued 1-6 hours prior to CABG. The objective was to demonstrate that a cangrelor IV infusion would maintain levels of platelet reactivity <240 P2Y12 Reaction Units (PRU) throughout the pre-operative period as measured by a P2Y12 assay. Platelet inhibition results are shown in this press release:

'/>"/>

Contact: Rebecca Hollins
rebecca.hollins@themedco.com
973-290-6081
The Medicines Company
Source:Eurekalert

0

GOOD

Page: 1 2
Related biology news :

1. Scripps research team solves structure of beneficial virus
2. Scripps research team sheds light on immune system suppression
3. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. Scripps research scientists identify blood component that turns bacteria virulent
6. Scripps research team defines new painkilling chemical pathway
7. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
8. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
9. Scripps scientists develop first examples of RNA that replicates itself indefinitely
10. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
11. Historical photographs expose decline in Floridas reef fish, new Scripps study finds

Post Your Comments:

Related Image:

Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT

(Date:6/17/2013)... with central nervous system infections may well be suffering ... to a study to be published in mBio ... for Microbiology. Researchers have detected the virus in spinal ... nervous system infections of unknown cause, and in an ... and poultry, suggesting animals may serve as reservoirs for ...

(Date:6/17/2013)... 2013How kids eat their food may turn out to be ... new study out of St. Michael,s Hospital. , The ... a significant association between poor eating habits in kids ... or "bad" cholesterol, putting them at risk for cardiovascular ... the Canadian Medical Association Journal today. , ...

(Date:6/17/2013)... original foundations with more modern elements. Using this same ... P. Dietrich School of Arts and Sciences have designed ... gas storage, and gas transport more efficient and at ... latest issue of the Journal of the American ... work builds upon Pitt Associate Professor of Chemistry Nathaniel ...

Breaking Biology News(10 mins):New virus discovered in patients with central nervous system infections 2 New virus discovered in patients with central nervous system infections 3 Poor eating behaviors may put preschoolers at risk for later health problems 2 'Chemical architects' build materials with potential applications in drug delivery and gas storage 2

[0] New virus discovered in patients with central nervous system infections [0] Poor eating behaviors may put preschoolers at risk for later health problems [0] 'Chemical architects' build materials with potential applications in drug delivery and gas storage

... for life on Earth stretches back billions of years, ... When multi-celled animal life appeared on the planet after ... rapidly. Conventional wisdom has it that animal ... much later in Earth history to terrestrial environments. ...

... Okla. In a first to the state of ... Natural Resources will receive $226,890 in grant funding from ... Resources Research Institute. OWRRI and USGS officials are ... the water cycle in the tallgrass prairie, two key ...

... nation-wide estimate of the tiger population brought a positive ... the Nepal Government,s Department of National Parks and Wildlife ... 194) breeding tigers in the wild within the four ... was jointly implemented by the DNPWC, Department of Forests ...

Cached Biology News:Earliest animals lived in a lake environment, research shows 2 Earliest animals lived in a lake environment, research shows 3 Key OSU water research receives national funding 2 121 breeding tigers estimated to be found in Nepal 2

Earliest animals lived in a lake environment, research shows Key OSU water research receives national funding 121 breeding tigers estimated to be found in Nepal

(Date:6/19/2013)... 2013 Express Diagnostics Int’l, Inc., manufacturer ... that it has received Class III medical device license ... DrugCheck® NxStep Onsite Drug Screen Cup in ... screening device in near-patient settings, such as physicians’ offices. ... Health Canada Class III approval for 24 different drugs ...

(Date:6/18/2013)... HONG KONG, June 18, 2013 China Cord ... the "Company"), China,s leading provider of cord blood collection, ... storage services, today announced its preliminary unaudited financial results ... year 2013 ended March 31, 2013. ... for the fourth quarter of fiscal 2013 increased by ...

(Date:6/18/2013)... June 18, 2013 Demanding industrial and ... engineered of synthetic Sapphire and Glass Ball Lenses, now ... Swiss Jewel Company , of Philadelphia , PA. ... and collimating the light beams without the need for ... and natural durability (9 mohs) make it the ideal ...

(Date:6/18/2013)... 18, 2013 RegeneCure announced ... proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane as a ... A common problem encountered when patients have a tooth replaced ... volume to house the implant. Consequently there is often a ... the natural bone regenerates. The bone substitute material, in turn, ...

[0] Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors [0] RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants

... May 15 DOR BioPharma, Inc. (OTC Bulletin Board: ... today announced its financial results for the first quarter ... 2009 were approximately $0.5 million compared to $0.7 million ... revenues were primarily attributable to decreased research and development ...

... ENMD-2076 Clinical Program Adds Leukemia Clinical Study and Orphan ... ENMD ), a clinical-stage pharmaceutical company developing ... for three of its clinical-stage drug candidates at the ... be held May 29 - June 2, 2009 in ...

... with unionsSEATTLE, May 15 Cell Therapeutics, Inc. (CTI) ... discussed in a press release on February 27, 2009, ... reached agreement with the employee union on a severance ... CTI,s total headcount in Italy by 56 positions in ...

Cached Biology Technology:DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 2 DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 3 DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 4 DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 5 EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 2 EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 3 EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 4 EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 5 Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses 2

DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses

... expression of an N-terminal FLAG® fusion and ... marker from bicistronic mRNA. Two genes ... for transcription of a single message from ... for protein-protein interaction studies, multi-subunit proteins, and ...

...

Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...

Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....

Biology Products:

pBICEP-CMV-3 Expression Vector from Sigma-Aldrich Eppendorf Thermomixer from Eppendorf North America Mouse Anti-Human SCARB2 Monoclonal Antibody, Unconjugated, Clone 1C8 from Abnova Corporation Rabbit Anti-Human SERPINF2 Polyclonal Antibody, Unconjugated from Atlas Antibodies